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Abstract
Background: Glioblastoma (GBM) is the most common and malignant primary intracranial human neoplasm. GBMs 
are characterized by the presence of extensive areas of necrosis and hypoxia. Hypoxia and its master regulator, hypoxia 
inducible factor 1 (HIF-1) play a key role in glioma invasion.
Results: To further elucidate the functional role of HIF-1α in glioma cell migration in vitro and in invasion in vivo, we 
used a shRNA approach to knock down HIF-1α expression complemented with genome-wide expression profiling, 
performed in both normoxic and hypoxic conditions. Our data show that knock down of HIF-1α in glioma cells 
significantly impairs their migration in vitro as well as their ability to invade into the brain parenchyma in vivo. Next, we 
assessed the role that HIF-1α plays in maintaining the characteristics of cancer stem cells (CSCs). By using the tumor 
sphere forming assay, we demonstrate that HIF-1α plays a role in the survival and self-renewal potential of CSCs. Finally, 
expression profiling experiments in glioma cells provided detailed insight into a broad range of specific biological 
pathways and processes downstream of HIF-1α. We discuss the role of these processes in the migratory and invasive 
properties, as well as the stem cell biology of glioblastomas
Conclusions: Our data show that knock down of HIF-1α in human and murine glioma cells impairs their migration in 
vitro and their invasion in vivo. In addition, our data suggest that HIF-1α plays a role in the survival and self-renewal 
potential of CSCs and identify genes that might further elucidate the role of HIF-1α in tumor migration, invasion and 
stem cell biology.
Background
Glioblastoma (GBM) is the most common and malignant
primary central nervous system tumor [1-3]. GBMs are
characterized by a high degree of invasion, angiogenesis
and the presence of necrosis [2,3]. In addition, these
tumors are hypoxic [4-6]. Hypoxia and its master regula-
tor hypoxia inducible factor 1 (HIF-1) play a key role in
glioma invasion [4,6]. In GBMs, HIF-1α is primarily
localized in pseudopalisading cells around areas of necro-
sis and in tumor cells infiltrating the brain at the invasive
edge of the tumor [6]. Its expression appears to be associ-
ated with intratumoral hypoxia and correlates with
glioma grade and vessel density, emphasizing its role in
brain tumor progression and angiogenesis [6]. In addition
to oxygen levels, HIF-1 expression can be affected by sev-
eral mechanisms including the activation of oncogenes
such as EGFR or loss of tumor suppressors, such as p53
or PTEN, both of which are common alterations found in
GBMs [4].
HIF-1 is a heterodimeric transcription factor that con-
sists of 2 subunits. The HIF-1β subunit is constitutively
expressed whereas the HIF-1α subunit is regulated by
oxygen levels. It is stable under hypoxic conditions but is
rapidly degraded under normoxic conditions [7]. After
stabilization or activation, HIF-1 translocates to the
nucleus where it induces the transcription of numerous
downstream target genes via their hypoxia response ele-
ments (HREs) [7]. One of the target genes is vascular
* Correspondence: dz4@nyu.edu
1 Microvascular and Molecular Neuro-oncology laboratory, New York University 
School of Medicine, New York University Langone Medical Center, New York, 
NY, USA
Full list of author information is available at the end of the articleMéndez et al. Molecular Cancer 2010, 9:133
http://www.molecular-cancer.com/content/9/1/133
Page 2 of 10
endothelial growth factor (VEGF), an important angio-
genic factor. HIF-1 acts as an activator of angiogenesis by
controlling the expression of VEGF as well as other
proangiogenic factors such as placenta-like growth factor
and platelet-derived growth factor β [4,5].
Growing evidence suggests the existence of a reservoir
of cells within the tumor that share similar properties
with normal stem cells and are capable of driving tumori-
genesis [8,9]. These cells, called cancer stem cells (CSCs)
or tumor initiating cells, have been described in several
tumor types including GBMs [9]. CSCs are cells with
extensive proliferation, self-renewal and tumor initiation
properties [10,11]. In addition, brain tumor stem cells
have the ability to grow as nonadherent spheres when
grown in the proper culture media [12]. It has been
shown that hypoxia is able to maintain the undifferenti-
ated state of stem cells [13]. Furthermore, it has been
shown that hypoxia is able to promote the survival and
proliferation of certain populations of neural stem cells or
neural progenitor cells [14].
To further elucidate the role that HIF-1α has in glioma
cell migration in vitro and in vivo, we knocked down the
expression of HIF-1α and evaluated the migration and
invasion potential of these glioma cells. In addition, we
assessed the role that HIF-1α plays in maintaining CSCs.
To identify genetic pathways that might be involved in
the reduced migration in vitro, the reduced invasiveness
in vivo and the reduced ability to form tumor spheres of
cells knocked down for HIF-1α, we performed gene
expression profiling analysis. Our data show that knock
down of HIF-1α in human and murine glioma cells
impairs their migration in vitro and their invasion into
the brain parenchyma in vivo. In addition, our data sug-
gest that HIF-1α plays a role in the survival and self-
renewal potential of CSCs and identify genes that might
further elucidate the role of HIF-1α in tumor migration,
invasion and stem cell biology.
Methods
Cell culture
The human glioma cell lines, LN308 (kindly provided by
Dr. F. Furnari from the Ludwig Institute for Cancer
Research, UCSD) and U87MG, the murine glioma cell
line GL261 tagged with green fluorescent protein (GFP)
[15], and the human embryonic kidney (HEK) 293T cells,
used for lentivirus production (kindly provided by Dr. M.
Pagano, New York University) were cultured in 5% CO2
and 95% humidified atmosphere air at 37°C in Dulbecco's
modified Eagle's medium (DMEM; Cellgro, Herndon,
VA), supplemented with 10% fetal bovine serum (FBS;
Atlanta Biologicals, Lawrenceville, GA), 1% penicillin and
streptomycin, and 2 mM glutamine (Gibco; Grand Island,
NY).
For hypoxic exposure, cells were placed in a sealed
Modular Incubator Chamber (Billups-Rothenberg Inc.,
Del Mar, CA) flushed with 1% O2, 5% CO2, and 94% N2
and incubated at 37°C for 16 h.
Western blot analysis
Cells (1 × 106) were seeded in 10 cm2 dishes in complete
growth medium. The following day, cells were exposed to
normoxic (20% O2) or hypoxic conditions (1% O2) for 16
h. Protein quantitation and electrophoresis was per-
formed as previously described [16]. Western blot analy-
sis was performed with the following antibodies: mouse
anti-HIF-1α monoclonal antibody used at 1:1000 (clone
54, BD Transduction Laboratories, San Jose, CA), rabbit
anti-HIF-1α used at 1:1000 (Cat. A300-286A Bethyl Lab-
oratories, Inc, Montgomery, TX) and mouse anti-actin
monoclonal antibody used at 1:20,000 (clone C4, Chemi-
con International, Inc., Temecula, CA). Sheep anti-mouse
and donkey anti-rabbit IgG (Amersham Life Pharmacia
Biotech, Piscataway, NJ) horseradish peroxidase-conju-
gated secondary antibodies were used at 1:2000. Immu-
nodetection was followed by visualization and
densitometry using Scion Image NIH Image software
(National Institutes of Health, Bethesda, MD).
Lentivirus production and infection of glioma cells
The shRNA directed against HIF-1α used to infect the
LN308 cell line (kindly provided by Dr. L. Gardner from
New York University) was (CCG GAG AGG TGG ATA
TGT CTG GGC TCG AGC CCA GAC ATA TCC ACC
TCT TTT TT) and the scramble sequence was (CCG
GGG GTC TGT ATA GGT GGA GAC TCG AGT CTC
CAC CTA TAC AGA CCC TTT TT). Five different
shRNA sequences directed against HIF-1α were pur-
chased from Open Biosystems (Huntsville, AL) and used
to knockdown human and mouse HIF-1α expression in
U87MG and GL261 glioma cell lines.
Recombinant lentiviruses were produced by cotrans-
fecting HEK 293T cells with the lentivirus expression vec-
tor (pLKO.1 puro) and packaging plasmids (Δ8.9 and vsv-
g) using Fugene 6 (Roche Diagnostics, Indianapolis, IN)
as a transfection reagent. Infectious lentiviruses were col-
lected at 24, 48 and 72 h after transfection and the pooled
supernatants centrifuged to remove cell debris and fil-
tered through a 0.45 μm filtration unit. GFP-tagged
murine GL261 and human glioma cells were infected and
stable transfectants were selected in puromycin for 7
days. After this time, cells were expanded and exposed to
normoxic or hypoxic conditions for 16 h to test for HIF-
1α downregulation. Two to three of the five shRNA
sequences were able to efficiently downregulate HIF-1α
expression in glioma cells based on Western blot analysis.
These lentivirus expression vectors (shHIF) were used for
further investigations.Méndez et al. Molecular Cancer 2010, 9:133
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Boyden chamber migration assay
BD Biocoat chambers (BD Biosciences Discovery Lab-
ware, Bedford, MA) with 8-μm pore size polystyrene fil-
ter inserts for 24-well plates were used according to the
manufacturer's instructions and as described [16]. Briefly,
cells (2 × 104) were seeded onto the upper compartment
of each chamber in 300 μl of DMEM with 10% FBS and
placed into wells containing 750 μl of complete medium
in the lower chamber. The migration chambers were
incubated for 16 h in normoxic or hypoxic conditions at
37°C. Following incubation, the inserts were fixed and
stained and the number of migrating cells was counted as
described [17]. Two independent experiments, done in
duplicate, were performed. Images were quantified using
Image-Pro Discovery software.
Animal experiments
Female C57BL/6 mice (10-12 weeks old) were purchased
from Taconic (Germantown, NY) and maintained in
accordance with the protocol approved by the Institu-
tional Animal Care and Use Committee. GFP-tagged
GL261 stable transfectants (1 × 105) expressing either the
empty vector or the HIF-1α shRNA sequence were
implanted stereotactically into mouse brains as previ-
ously described [18]. Animals were sacrificed when they
became moribund and brains were removed and pro-
cessed for paraffin embedding. Tumors in the hematoxy-
lin and eosin (H&E) coronal sections were measured to
determine tumor volumes and depth of invasion. Tumor
volume was calculated using the formula: L × S2 × 1/2,
where L is the longest tumor diameter and S the shortest
tumor diameter as described [19]. To assess depth of
invasion, H&E and GFP stained slides were photographed
at × 4 using a resolution of 432 dpi. Images were assem-
bled using Adobe Photoshop CS3 Extended Software. A
line was drawn along each evaluable surface, establishing
a border of the tumor core without any invading cells or
projections of groups of cells. A tumor with 0% of inva-
sion would have a true tumor border falling directly on
this line. Then, at an interval of 200 to 400 pixels along
this line, measurements were taken from the previously
drawn line to the furthest invading cell perpendicular to
solid line away from the tumor border corresponding to
the drawn line. Two independent experiments were per-
formed. The total number of measurements for each
tumor was analyzed for statistical significance. The num-
ber of measurements per animal averaged 64.
Immunohistochemistry
To determine HIF-1α expression, sections were stained
using the Catalyzed Signal Amplification System (DAKO,
Carpinteria, CA). After deparaffinization and rehydra-
tion, slides were treated with target retrieval solution
(DAKO) at 97°C for 45 min. Nuclei were counterstained
with hematoxylin. Negative controls were done with non-
immune serum or PBS used instead of primary antibody.
Primary antibody was used as follows: HIF-1α 1:300
(Bethyl Laboratories). Automated analysis was done on a
Tech-Mate 100 automated stainer (Ventana-BioTek Solu-
tions, Inc., Tucson, AZ).
Tumor sphere forming assay
Cells were diluted in serum-free growth medium (1000
cells/ml) and plated in 100 μl in non-tissue culture coated
96-well plate. Cells were fed with 25 μl of serum-free
growth medium every other day, for 14 days. The culture
medium consisted of serum-free DMEM/F12 (Invitro-
gen, Grand Island, NY) supplemented with 10 U/ml hep-
arin, 2% B27 (Invitrogen), human recombinant fibroblast
growth factor 2 (FGF-2, 20 ng/ml, Sigma-Aldrich, St.
Louis, MO) and epidermal growth factor (EGF, 20 ng/ml,
Sigma-Aldrich). After 14 days, spheres were measured
and those > 100 μm were counted as a tumor sphere
forming unit. The data calculated for the number and size
of the tumor spheres is the average of three independent
experiments. Spheres were counted and measured from
32 different wells/cell line/experiment.
cRNA preparation and microarray hybridization
Total RNA was extracted using Trizol (Invitrogen) as pre-
viously described [20], from GL261 control and GL261
shHIF cells after 16 h of incubation in either normoxic or
hypoxic conditions. RNA quality and quantity was deter-
mined using Agilent 2100 Bioanalyzer and Nanodrop
ND-1000. 5 μg of total RNA were used to prepare cRNA
following the Affymetrix one-cycle labeling protocol and
standardized array processing procedures recommended
by Affymetrix (Santa Clara, CA), including hybridization,
fluidics processing and scanning of the Affymetrix mouse
Genechip MG-430A 2.0 arrays containing 22,000 probes
(14,000 well-characterized mouse genes). Two indepen-
d e n t  e x p e r i m e n t s  w e r e  p e r f o r m e d .  D u p l i c a t e s  o f  e a c h
studied condition (control vs. shHIF in normoxia vs.
hypoxia) were processed for microarray analysis.
Array data analysis
The raw data (Affymetrix CEL files) were normalized
using Robust Multichip Average algorithm (RMA) [21] in
GeneSpring GX software (Agilent Technologies, Santa
Clara, CA). Genes/mRNAs differentially regulated
between the studied conditions were identified by feature
selection algorithm Pavlidis Template Matching (PTM, p
< 0.05) incorporated in the Multi-experiment Viewer of
the TIGR TM4 Analysis package [22]. Gene lists resulting
from the statistical analysis results were further thresh-
olded based on fold difference in expression (> 30%). The
GO (Gene Ontology) and KEGG (Kyoto Encyclopedia of
Genes and Genomes) pathway functional annotationsMéndez et al. Molecular Cancer 2010, 9:133
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were performed using the web-based tool DAVID bioin-
formatics resources [23].
Statistical methodologies
Statistical significance was determined by unpaired t-test
(GraphPad Prism Software).
Results
Knock down of HIF-1α reduces hypoxia-induced HIF-1α 
expression in glioma cells
In order to understand the role that HIF-1α plays in
glioma cell invasion, we used a shRNA approach to knock
down its expression. We studied how hypoxia, a common
feature of human GBMs, can affect this behavior in vitro.
T o accomplish this, we used stable transfectants (shHIF
and control) of both human (LN308 and U87MG) and
murine (GL261) glioma cell lines and compared the levels
o f  e x p r e s s i o n  o f  H I F - 1 α  u n d e r  b o t h  n o r m o x i c  a n d
hypoxic conditions (Figure 1A).
Under hypoxic conditions, all glioma cell lines used as a
control showed induction of HIF-1α. HIF-1α levels of
expression were increased in LN308, U87MG and GL261
cells by 9-, 2- and 14-fold, respectively. We detected two
HIF-1α bands under hypoxic conditions. It has been
shown that HIF-1α is expressed as two bands that repre-
sent post-translational modifications [24]. In contrast,
when HIF-1α expression was knocked down in human
and murine glioma cells the levels of HIF-1α were lower
in normoxic conditions and failed to become upregulated
in hypoxic conditions (Figure 1A).
Knock down of HIF-1α reduces hypoxia-induced migration 
of glioma cells in the Boyden chamber assay
T o study the role of HIF-1α and hypoxia in glioma cell
migration we analyzed the ability of stable transfectants
expressing shHIF to migrate under both normoxic and
hypoxic conditions using the Boyden chamber assay (Fig-
ure 1B). In hypoxic conditions, all cell lines increased
their migration significantly compared to control cultures
in normoxic conditions (p < 0.001). In all cases, the con-
trol glioma cells showed significantly higher numbers of
migrated cells under normoxic conditions compared with
cells knocked down for HIF-1α expression (p < 0.0001).
Only murine GL261 cells knocked down for HIF-1α
expression showed a significant increase in migration in
hypoxic conditions compared to similar cultures in nor-
moxic conditions (p < 0.001). Nevertheless, under both
normoxic and hypoxic conditions, knock down of HIF-1α
significantly reduced the number of migrated cells in all
cell lines (p < 0.0001).
Knock down of HIF-1α reduces invasion of murine glioma 
cells in vivo
GL261 cells infected either with the empty vector or a
HIF-1α shRNA were injected into the brains of C57BL/6
mice. Animals were sacrificed when they became mori-
bund. Brains were harvested and processed for histopa-
thology and immunohistochemistry.
There was no significant difference in the average sur-
vival between the two groups. Animals injected with con-
trol cells survived 24.1 ± 1.8 days compared with 26.0 ±
1.7 days for animals injected with shHIF cells. Consistent
with survival outcome, tumor volumes showed no signifi-
cant differences between the two groups. Tumors derived
from cells infected with the empty vector had volumes of
64.9 ± 17.5 mm3 compared with volumes of 77.1 ± 12.5
mm3 in tumors derived from cells knocked down for HIF-
1α.
Importantly, tumors derived from cells lacking HIF-1α
expression were significantly less invasive compared with
control tumors expressing HIF-1α, as assessed by both
immunofluorescence for GFP and H&E staining (Figure
2). The mean depth of invasion in control tumors was
86.1 ± 6.2 μm compared with 59.4 ± 9.1 μm in tumors
derived from cells knocked down for HIF-1α (p = 0.03).
Immunostaining of tumor sections for HIF-1α expres-
sion confirmed that the tumors resulting from the injec-
tion of shHIF cells had decreased HIF-1α expression
compared with control tumors resulting from the injec-
tion of cells infected with the empty vector (Figure 2B).
Figure 1 Knock down of HIF-1α reduces hypoxia-induced HIF-1α 
expression and hypoxia-induced migration of glioma cells. (A) 
Western blot showing the expression level of HIF-1α under normoxic 
(Norm) and hypoxic (Hyp) conditions in human (LN308 and U87MG), 
and murine (GL261) glioma cell lines, after HIF-1α shRNA lentivirus-me-
diated infection (shHIF). β-Actin was used as loading control. A repre-
sentative result of two independent experiments is shown. (B) Knock 
down of HIF-1α reduces hypoxia-induced migration of glioma cells. 
Boyden chamber assays showing migration of human (LN308 and 
U87MG) and murine (GL261) glioma cell lines infected with HIF-1 shR-
NA (shHIF) or the control cells. Two independent experiments, done in 
duplicate, were performed. Each graph represents the number of cells 
per field counted after 16 h of migration in either a normoxic (Norm) or 
a hypoxic (Hyp) environment (three asterisks, p < 0.0001).Méndez et al. Molecular Cancer 2010, 9:133
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Knock down of HIF-1α reduces the ability of murine glioma 
cells to form tumor spheres
It has been shown that when grown in anchorage-inde-
pendent and serum-free conditions, glioma cells are able
to form tumor spheres. These tumor-derived spheres are
known to be enriched in CSCs [25]. Cells infected with
the empty vector or knocked down for HIF-1α were
plated in the tumor sphere forming assay and the number
and size of the tumor spheres were analyzed on day 14.
Cells knocked down for HIF-1α formed significantly
fewer tumor spheres than control cells. The shHIF cells
formed 60% fewer tumor spheres compared with the
number of tumor spheres formed by the control cells (p =
0.02) (Figure 3A). In addition, the size of the tumor
spheres was also significantly reduced in cells knocked
down for HIF-1α. The average diameter of the spheres
formed by control cells was 240.6 ± 2.8 μm compared
with 167.4 ± 4.1 μm for the spheres formed by shHIF cells
(p < 0.0001) (Figure 3B).
Knock down of HIF-1α alters the gene expression profile 
induced by hypoxia
To identify genetic pathways in shHIF cells that might be
involved in the reduced migration in vitro, the reduced
invasiveness  in vivo and the reduced ability to form
tumor spheres, we performed gene expression profiling
using Affymetrix oligonucleotide arrays. Cells infected
with the empty vector or knocked down for HIF-1α were
grown under normoxic or hypoxic conditions for 16 h.
Two independent experiments were performed and sub-
jected to statistical analysis that identified reproducibly
modulated genes correlating and potentially functionally
Figure 3 Knock down of HIF-1α reduces the ability of murine glio-
ma cells to form tumor spheres. Primary tumor sphere forming ca-
pacity of GL261 shHIF cells in comparison with control cells. Three 
independent experiments were performed. (A) Bar graph represents 
the % of the total number of tumor spheres in shHIF cells versus the 
control. Knockdown of HIF-1α significantly reduces the ability of glio-
ma cells to form tumor spheres. The shHIF cells formed 60% fewer tu-
mor spheres compared with control cells (asterisk denotes p = 0.02). 
(B) Bar graph represents the average diameter (μm) of tumor spheres 
in shHIF cells versus the control. Lack of HIF-1α significantly reduces the 
average diameter of the spheres formed (167.4 ± 4.1 μm) compared 
with the size of those derived from control cells (240.6 ± 2.8 μm) (three 
asterisks denotes p < 0.0001). (C) Representative images of tumor 
spheres derived from either control or shHIF cells.
Figure 2 Knock down of HIF-1α reduces invasion of murine glio-
ma cells in vivo. Representative tumors derived from GFP-tagged 
GL261 shHIF-1 and control cells showing tumor sections stained for 
GFP, H&E and HIF-1α. (A) The bar graph represents the average depth 
of invasion (μm) at the edge of tumors derived from GL261 control and 
GL261 shHIF cells (N = 7/group) (asterisk denotes p = 0.03). (B) As 
shown by GFP staining and confirmed by H&E, control tumors derived 
from cells expressing HIF-1α displayed an invasive edge compared 
with tumors derived from GL261 shHIF-1 cells with marginal invasion. 
HIF-1α immunohistochemistry confirms lack of HIF-1 expression in 
HIF-1α knockdown tumors and its expression in the controls. Open ar-
rowheads point to HIF-1α expressing cells at the infiltrative margin in 
the control tumors. Scale bar represents 50 μm.Méndez et al. Molecular Cancer 2010, 9:133
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associated with the altered characteristics identified in
shHIF cells.
The analysis of the genes that were upregulated in the
control cells in response to hypoxia showed a number of
known HIF-1α target genes such as Bnip3, P4ha1, Ak3l1,
Bhlhe40, Slc2a1 (GLUT1), Vegfa, Hk2, Ccng2 and P4ha2
(Table 1). In contrast, when shHIF cells were exposed to
hypoxia, the same genes failed to become upregulated,
validating our shRNA approach to block HIF-1α expres-
sion, and the response of shHIF cells to hypoxia. When
we analyzed the genes that were reproducibly upregu-
lated in response to hypoxia in the control cells but
showed neither increase nor downregulation in shHIF
cells, using as normalization baseline the GL261 control
cells in normoxia, we identified 149 Affymetrix probe
sets (Figure 4). Using this normalization, the levels of
Vegfa, a well known HIF-1α target, showed a 2.2 fold
increase in response to hypoxia in GL261 control cells. In
contrast, Vegfa levels in shHIF cells did not show a
h y p o x i c  u p r e g u l a t i o n  ( A d d i t i o n a l  f i l e  1 ,  F i g u r e  S 1 ) .
Although HIF-1α has been recognized as a potent stimu-
lator of VEGF expression, there are other molecules that
control VEGF expression by positive or negative feedback
loops. In Figure 4, we show the Box plot analysis (Figure
4A) and the heat map (Figure 4B) of the probe sets that
follow this distinct profile with the statistical significance
described in Material and Methods. The complete and
fully annotated set of 149 genes identified by this analysis
is shown in Additional file 2, Table S1.
Genes differentially expressed in response to hypoxia in 
shHIF cells versus control cells
Next, we analyzed those genes that showed differential
expression under hypoxic conditions, either up- or down-
regulated, in the shHIF cells compared with the control
cells (Table 2). The table shows the fold differences for
genes that are differentially expressed between shHIF and
control cells in hypoxic conditions. Some genes were
upregulated in response to hypoxia in shHIF cells despite
the absence of HIF-1α expression. This gene set included
Thrombospondin 1 and the member of the DNA damage
repair response effectors H2afx (Table 2). Among the
genes that were downregulated in shHIF cells in response
to hypoxia were Adamts-5, MAP4K4, Jmjd1 and Cerulo-
plasmin. Reduced levels of the metalloprotease Adamts-5
and the mitogen-activated protein kinase MAP4K4 might
contribute to the less invasive nature of shHIF tumors.
Downregulation of Jmjd1 and Ceruloplasmin, genes asso-
ciated with stem cells, might be correlated with the poor
ability of shHIF cells to grow as tumor spheres.
Pathway analysis of HIF-1α-dependent genetic programs
The GO and KEGG pathway functional annotations of
genes differentially expressed in response to hypoxia in
shHIF cells functionally grouped genes predominantly
involved in DNA repair (Rad50, Rad21, Rad52,
Trp53bp1), cell adhesion (Col17a1, Twist1) and cell
migration (Ephb3, Kitl, Erbb2) among others. We also
detected several genes of the Wnt (Fzd2, Fzd6, Tcf7l2)
and the TGF-β pathway (Smad4, Smad2, Map3K7) (Addi-
tional file 3, Table S2). Taken together, the alteration of
expression of these genes and pathways might be associ-
ated with the decreased migration and invasion potential
of shHIF cells.
Discussion
This study shows that knock down of HIF-1α in glioma
cells results in i) reduced migration in vitro, ii) decreased
invasion  in vivo, iii) reduced ability to form tumor
spheres and iv) altered gene expression profiles under
hypoxic conditions. The results identified genes that
Table 1: HIF-1α target genes upregulated in response to hypoxia in GL261 control cells
Affymetrix ID Gene Symbol Gene Title Fold Difference SD
1422470_at Bnip3 BCL2/adenovirus E1B 19kDa-interacting protein 1, NIP3 7.83 ± 2.26
1452094_at P4ha1 Procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), 
alpha 1 polypeptide
3.46 ± 0.60
1421830_at Ak3l1 Adenylate kinase 3-like 1 3.09 ± 0.58
1418025_at Bhlhe40 Basic helix-loop-helix family, member e40 2.54 ± 0.04
1426599_a_at Slc2a1 Solute carrier family 2 (facilitated glucose transporter), member 1 2.24 ± 0.03
1420909_at Vegfa Vascular endothelial growth factor A 2.19 ± 0.48
1422612_at Hk2 Hexokinase 2 2.08 ± 0.20
1416488_at Ccng2 Cyclin G2 2.05 ± 0.60
1417149_at P4ha2 Procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), 
alpha II polypeptide
2.05 ± 0.12
List of HIF-1α target genes found in the gene expression profile experiment as upregulated in response to hypoxia in GL261 control cells. For each 
gene the Affymetrix ID, the gene symbol, gene title, average fold difference and standard deviation (n = 2) are shown.Méndez et al. Molecular Cancer 2010, 9:133
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might contribute to glioma cell invasion induced by
hypoxia.
Hypoxia is a critical aspect of the glioma microenviron-
ment, and it has been associated with poor prognosis,
increased angiogenesis, tumor growth and resistance to
radio- and chemotherapy [26]. HIF-1α, the key hypoxia
regulatory factor, has been shown to be important in pro-
moting both angiogenesis and invasion [4]. The role that
hypoxia plays in glioma cell migration is well established
[17,27,28]. Our in vitro data show that hypoxia increases
migration of human and murine glioma cells. The shRNA
approach directed towards HIF-1α resulted in reduced
migration of human and murine glioma cells knocked
down for HIF-1α compared with control cells with nor-
mal HIF-1α expression. These data support the role of
HIF-1α and hypoxia in glioma cell migration.
Our data did not show any significant differences in
overall survival or tumor volume between animals
injected with cells knocked down for HIF-1α expression
or control cells. Some studies showed that reduction of
HIF-1α levels by siRNA in glioma cells grown in mouse
flanks decreased tumor growth which was associated
with reduction of VEGF and GLUT-1, two known down-
stream targets of HIF-1α [29]. In another study, HIF-1α
deficient teratomas grew faster, despite reduced vascular-
ization, due to reduced apoptosis [30]. A similar result,
showing reduced vascularization and accelerated tumor
growth, was obtained with glioma cells injected subcuta-
neously, and expressing a HIF dominant negative con-
struct [31]. HIF-1α is commonly expressed in tumors,
though the role that HIF-1α deficiency plays in tumor
growth is not fully understood.
It is important to consider the role of the interaction
between the tumor cells and the host brain microenvi-
ronment on the invasion ability of tumor cells. Our data
show that inhibition of HIF-1α by expression of a stable
shRNA alters the growth pattern of glioma cells in the
brain microenvironment. Tumors with lower HIF-1α
expression are less invasive, as seen by a better defined
border, while tumors derived from control cells demon-
strated an irregular infiltrating edge. In concordance with
our results, glioma cells knocked down for HIF-1α using
an siRNA approach failed to invade the surrounding
brain tissue, as assessed using an organotypic brain slice
model [28].
There is growing evidence that in GBMs, as in other
solid tumors, a small fraction of cells that have tumor ini-
tiating properties are present. These cells are defined as
CSCs. GL261 glioma cells form neurospheres when
grown in a serum free medium supplemented with FGF
and EGF . Neurospheres are enriched in CSCs [25]. One
study showed that neurospheres derived from GL261
cells resulted in more infiltrative and angiogenic tumors
when implanted into the brains of mice [32]. Our data
Figure 4 Profile of genes that are upregulated in response to hy-
poxia in GL261 control cells and show no change or downregula-
tion in GL261 shHIF cells, using as normalization baseline the 
GL261 control cells in normoxia. For each cell line (control and 
shHIF) and condition: Norm (Normoxia) and Hyp (Hypoxia) we show 
the results from two independent experiments used in the analysis (R1 
and R2). (A) Box plot analysis shows a five-number summary (the small-
est observation, lower quartile, median, upper quartile, and largest ob-
servation) for the 149 significantly modulated Affymetrix Probe sets, 
found by Pavlidis Template Matching (p < 0.05), based on two individ-
ual experiments (R1 and R2). (B) Heat map showing the 149 Affymetrix 
probe sets including known HIF-1α targets that are upregulated in re-
sponse to hypoxia in GL261 control cells and show no change or 
downregulation in GL261 shHIF cells. Red and blue colors denote in-
creased and decreased mRNA abundance, respectively.Méndez et al. Molecular Cancer 2010, 9:133
http://www.molecular-cancer.com/content/9/1/133
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show that when HIF-1α expression is knocked down, the
ability of GL261 cells to form tumor spheres is signifi-
cantly reduced compared with the control cells. Although
the reduced number and size of tumor spheres did not
inhibit tumor growth in vivo, it correlated with reduced
invasion of glioma cells into the brain parenchyma. Can-
cer stem cells are believed to persist in tumors and cause
tumor recurrence and invasion, rendering conventional
therapies ineffective. Therefore, a reduction in the num-
ber of tumor spheres might have important implications
for decreasing the invasive potential of glioma cells.
Recently Zhao et al. showed that knock down of HIF-1α
was able to block the hypoxia induced migration of neural
stem cells. This decrease in migration was due to reduced
l e v e l s  o f  H I F - 1 α  a n d  i t s  d o w n s t r e a m  t a r g e t s ,  s u c h  a s
CXCR4 [33]. Additionally, Li et al. recently showed that
knock down of HIF-1α or HIF-2α in glioma stem cells
impaired tumor sphere formation [34]. Hypoxia was
r e p o r t e d  t o  l e a d  t o  a n  e n r i c h m e n t  i n  n e u r a l  s t e m  c e l l
markers [35], and reduction of HIF-1α levels abrogated
this effect [36]. These studies, together with our findings,
reinforce the importance of hypoxia and HIF-1α in can-
cer stem cell biology. Our data also suggest a relationship
between a reduction in the number of tumor spheres and
decreased invasiveness of glioma cells.
The hypoxic response driven by HIF-1α regulates the
expression of genes involved in angiogenesis, invasion
and epithelial-mesenchymal transition, indicating its role
in local invasion [37,38]. The gene expression analysis
identified genes and pathways that might further eluci-
date the role of HIF-1α in glioma invasion. Our analysis
shows that when GL261 control cells were exposed to
hypoxia, known HIF-1α targets such as Bnip3, P4ha1,
Ak3l1, Bhlhe40, Slc2a1, Vegfa, HK2, Ccng2 and P4ha2
were upregulated. In contrast, these genes failed to
become upregulated in cells knocked down for HIF-1α
after hypoxia exposure.
Two of the genes identified through gene expression
analysis that were downregulated in shHIF hypoxic cells,
Adamts-5 and MAP4K4, might contribute to the less
invasive growth of the GL261 tumors that we observed.
Adamts-5 is a desintegrin and metalloproteinase with
thrombospondin motifs that is able to degrade brevican,
one of the components of the brain extracellular matrix.
It has been shown that Adamts-5 is overexpressed in
glioma cells compared with normal brain tissue and is
involved in glioma invasion [39]. Degradation of brevican
may facilitate the invasion of glioma cells to the sur-
rounding brain tissue [40]. MAP4K4 is a serine/threonine
kinase commonly overexpressed in tumors. Its role in
tumor progression was demonstrated using siRNA.
Knock down of MAP4K4 resulted in inhibition of tumor
cell migration and invasion [41], [42]. In contrast, overex-
pression of MAP4K4 increased invasion in the presence
of hepatocyte growth factor [43].
Some of the genes upregulated in response to hypoxia
in shHIF cells were Thrombospondin 1 and H2afx that
might contribute to reduced migration in vitro and inva-
sion  in vivo. Thrombospondin 1 is a multifunctional
extracellular matrix protein that functions as an angio-
genic inhibitor and is involved in activating latent TGF-β
secreted by tumor cells [44]. Thrombospondin 1 inversely
correlates with invasiveness and lymph node metastasis,
and in lung adenocarcinoma cells it has been shown to
Table 2: Genes differentially expressed in response to hypoxia in shHIF cells versus control cells
Affymetrix ID Gene Symbol Gene Title Fold Difference SD
1460302_at Thbs1 Thrombospondin 1 11.76 ± 2.27
1416746_at H2afx H2A histone family, 
member X
5.23 ± 0.19
1422561_at Adamts5 A disintegrin-like and 
metalloprotease 
(reprolysin type) with 
thrombospondin type 
1 motif, 5 
(aggrecanase-2)
0.49 ± 0.03
1448050_s_at Map4k4 Mitogen-activated 
protein kinase kinase 
kinase kinase 4
0.33 ± 0.02
1417495_×_at Cp Ceruloplasmin 0.25 ± 0.01
1426810_at Jmjd1 Jumonji domain 
containing 1
0.15 ± 0.02
The fold differences for genes that are differentially expressed between shHIF and control cells in hypoxic conditions. For each gene the 
Affymetrix ID, the gene symbol, gene title, average fold difference and standard deviation (n = 2) are shownMéndez et al. Molecular Cancer 2010, 9:133
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directly inhibit invasion [45]. In endothelial cells, its over-
expression reduces their migration ability in vitro [46].
H2afx, a member of the DNA damage repair response
effectors is needed for endothelial cells to maintain their
proliferation under hypoxic conditions and is crucial for
hypoxia-driven neovascularization [47].
Two of the genes that might be associated with the poor
ability of shHIF cells to grow as tumor spheres are Jmjd1
and Ceruloplasmin. Both genes are downregulated in
shHIF cells exposed to hypoxic conditions. Jmjd1, a
known HIF-1α target, is a histone demethylase positively
regulated by the ES cell transcription factor Oct4. Jmjd1
has been shown to be critical in the maintenance of pluri-
potency of stem cells [48]. Ceruloplasmin is a copper pro-
tein inducible by hypoxia. Its expression has been shown
to be enriched in highly malignant glioma stem-like cells
[49].
Conclusions
Taken together, our in vitro and in vivo data confirm the
functional importance of HIF-1α in the invasive ability of
GBM cells. Glioma cells with reduced HIF-1α expression
and their response to hypoxia results in cells with
reduced migration ability, overall less invasive tumors,
and reduced ability to form tumor spheres. These obser-
vations, together with the gene expression analysis data,
highlight the role of HIF-1α in glioma invasion and stem
cell biology and identify genes that might further eluci-
date its role in tumor initiation and invasiveness.
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